Drug allergy to CFTR modulator therapy associated with lumacaftor-specific CD4+ T lymphocytes
- 1 February 2021
- journal article
- research article
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 147 (2) , 753-756
Abstract
No abstract availableKeywords
Funding Information
- Biotechnology and Biological Sciences Research Council
This publication has 8 references indexed in Scilit:
- Cystic Fibrosis: Emergence of Highly Effective Targeted Therapeutics and Potential Clinical ImplicationsAmerican Journal of Respiratory and Critical Care Medicine, 2020
- Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trialThe Lancet, 2019
- Immune pathomechanism and classification of drug hypersensitivityAllergy, 2019
- β-Lactam hypersensitivity involves expansion of circulating and skin-resident TH22 cellsJournal of Allergy and Clinical Immunology, 2018
- Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508delCFTRNew England Journal of Medicine, 2015
- Hypersensitivity to antibiotics in patients with cystic fibrosisJournal of Cystic Fibrosis, 2014
- Nonimmediate β-lactam reactions in patients with cystic fibrosisCurrent Opinion in Allergy and Clinical Immunology, 2012
- Beta-lactam allergy in adults with cystic fibrosisJournal of Cystic Fibrosis, 2007